Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide

Breast J. 2011 Sep-Oct;17(5):536-8. doi: 10.1111/j.1524-4741.2011.01144.x. Epub 2011 Aug 9.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adolescent
  • Adult
  • Age Factors
  • Amenorrhea / chemically induced*
  • Amenorrhea / genetics
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cytochrome P-450 Enzyme System / genetics*
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Female
  • Gene Frequency
  • Humans
  • Middle Aged
  • Pilot Projects
  • Polymorphism, Single Nucleotide
  • Primary Ovarian Insufficiency / chemically induced*
  • Primary Ovarian Insufficiency / genetics
  • Young Adult

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Cytochrome P-450 Enzyme System